NCT04424251View on ClinicalTrials.gov

Efficacy and Safety of HSK21542 in Inducing Postoperative Analgesia in Undergoing Elective Laparoscopic Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

July 2, 2020

Primary Completion Date

December 7, 2020

Study Completion Date

January 5, 2021

Conditions
Analgesia
Interventions
DRUG

Experimental: stage I：HSK21542 0.4 μg/kg

Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations

DRUG

Experimental: stage I：HSK21542 1 μg/kg

Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations

DRUG

Experimental: stage I：HSK21542 0.5μg/kg

once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

DRUG

Experimental: stage I：HSK21542 1μg/kg

once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

DRUG

Experimental: stage II：HSK21542 0.5μg/kg

once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

DRUG

Experimental: stage II：HSK21542 1μg/kg

once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

DRUG

Placebo

once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

Trial Locations (1)

Unknown

Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT04424251 - Efficacy and Safety of HSK21542 in Inducing Postoperative Analgesia in Undergoing Elective Laparoscopic Surgery | Biotech Hunter | Biotech Hunter